VBL Therapeutics to Present at the Oppenheimer 27t
Post# of 301275
TEL AVIV, Israel, March 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the Oppenheimer 27 th Annual Healthcare Conference, being held March 21-22, 2017 at the New York Grand Central Hotel in New York City.
| VBL Therapeutics Presentation Details @ Oppenheimer 27 th Annual Healthcare Conference | |
| Date: | Wednesday, March 22 |
| Time: | 9:10am Eastern Time |
| Presentation Room: | Track #3 |
About VBL Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC (646) 597-6979
(0)
(0)